Please login to the form below

Not currently logged in
Email:
Password:

Editas Medicine names James Mullen as chairman

He has previously served as CEO of Patheon

Jim MullenGenome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.

Mullen has over 30 years’ experience leading biotechnology and pharmaceutical organisations on a global scale.

Previously, Mullen has served as chief executive officer of Patheon, a pharmaceutical development and manufacturing services provider, until its acquisition by Thermo Fisher Scientific last year.

Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.

Katrine Bosley, president and chief executive officer of Editas Medicine, said: “Jim is a renowned leader in the biotechnology industry with deep experience building global companies and guiding corporate strategy, and I am very pleased to welcome his as chairman of the board.

“Jim’s extensive experience in driving excellence across R&D, commercialisation, manufacturing, business development and capital formation will be invaluable as we continue to build a genomic medicine leader and develop medicines for patients in the years to come.”

In addition, the company announced that Alexis Borisy and John Mendlein stepped down from the board.

12th April 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....